Status:
ACTIVE_NOT_RECRUITING
Atrioventricular Block and Cluster Headache (SEVA)
Lead Sponsor:
Centre Hospitalier Universitaire de Nice
Conditions:
Cluster Headache
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Verapamil is a calcium channel blocker widely used to treat cardiovascular diseases however it is also the first line treatment in the prevention of cluster headaches. In France, its prescription in t...
Eligibility Criteria
Inclusion
- patient 18 years old, and older
- patient suffering from Cluster Headache (according to the l'ICHD-3 diagnostic criterias)
- patients affiliated to the social security
- patient that has given his full written consent to participate in the study
- female patients participating in the study must be using an efficient contraception for more than 1 month prior to the beginning of the study
Exclusion
- patient presenting contraindications to the use of verapamil
- patient observing a treatment with ivabradine (Procoralan®), bétablockers, colchicine, l'esmolol, triazolam, quinidine.
- patient under justicial protection
- patient breastfeeding, or pregnant
- patient suffering from a neuromuscular transmisson disease
- patient with a pacemaker
Key Trial Info
Start Date :
November 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
September 5 2027
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT04406259
Start Date
November 2 2020
End Date
September 5 2027
Last Update
December 2 2025
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
CHU de Nice
Nice, CHUN, France, 06003
2
AP-HP Hôpital la Timone
Marseille, France, 13005